Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In this study patients with resectable basal cell carcinoma (BCC) who usually undergo surgery
without prior anticancer treatment will be treated with antitumor medication. But since BCC
is mainly localized in clearly visible regions of the body, as e.g. the face, there is also a
need to reduce scars as a consequence of surgery which will be accomplished by neoadjuvant
therapy.
The used medication - vismodegib - displays controllable adverse events and shows a good
efficacy for reduction of BCC lesions. It is expected that the neoadjuvant setting will lead
to minor surgical intervention thus minimising surgical risks and scars for the patients.